A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása: Magyar konszenzusajánlás

B. Hunyady, Gerlei Zsuzsanna, Gervain Judit, Horváth Gábor, G. Lengyel, A. Pár, Péter Zoltán, Rókusz László, Schneider Ferenc, F. Szalay, Tornai István, Werling Klára, Makara Mihály

Research output: Article

2 Citations (Scopus)

Abstract

Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred.

Original languageHungarian
Pages (from-to)3-22
Number of pages20
JournalOrvosi Hetilap
Volume158
DOIs
Publication statusPublished - febr. 1 2017

Fingerprint

Hungary
Hepacivirus
Liver Diseases
Guidelines
Therapeutics
Liver Cirrhosis
Interferons
Antiviral Agents
Costs and Cost Analysis
Ribavirin
Poisons
National Health Programs
Budgets
Hepatitis C
Organizations
Inflammation
Physicians
Liver

Keywords

  • Direct acting antiviral drug
  • Genotype
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Interferon
  • Liver cirrhosis
  • Polymerase inhibitor
  • Protease inhibitor
  • Replication complex inhibitor
  • Viral hepatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása : Magyar konszenzusajánlás. / Hunyady, B.; Zsuzsanna, Gerlei; Judit, Gervain; Gábor, Horváth; Lengyel, G.; Pár, A.; Zoltán, Péter; László, Rókusz; Ferenc, Schneider; Szalay, F.; István, Tornai; Klára, Werling; Mihály, Makara.

In: Orvosi Hetilap, Vol. 158, 01.02.2017, p. 3-22.

Research output: Article

Hunyady, B. ; Zsuzsanna, Gerlei ; Judit, Gervain ; Gábor, Horváth ; Lengyel, G. ; Pár, A. ; Zoltán, Péter ; László, Rókusz ; Ferenc, Schneider ; Szalay, F. ; István, Tornai ; Klára, Werling ; Mihály, Makara. / A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása : Magyar konszenzusajánlás. In: Orvosi Hetilap. 2017 ; Vol. 158. pp. 3-22.
@article{b9a35a6d0a614e258f1258536a69d679,
title = "A hepatitis C-v{\'i}rus-fertoz{\'e}s szur{\'e}se, diagnosztik{\'a}ja, antivir{\'a}lis ter{\'a}pi{\'a}ja, kezel{\'e}s ut{\'a}ni gondoz{\'a}sa: Magyar konszenzusaj{\'a}nl{\'a}s",
abstract = "Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred.",
keywords = "Direct acting antiviral drug, Genotype, Hepatitis C virus, Hepatocellular carcinoma, Interferon, Liver cirrhosis, Polymerase inhibitor, Protease inhibitor, Replication complex inhibitor, Viral hepatitis",
author = "B. Hunyady and Gerlei Zsuzsanna and Gervain Judit and Horv{\'a}th G{\'a}bor and G. Lengyel and A. P{\'a}r and P{\'e}ter Zolt{\'a}n and R{\'o}kusz L{\'a}szl{\'o} and Schneider Ferenc and F. Szalay and Tornai Istv{\'a}n and Werling Kl{\'a}ra and Makara Mih{\'a}ly",
year = "2017",
month = "2",
day = "1",
doi = "10.1556/650.2017.30688",
language = "Hungarian",
volume = "158",
pages = "3--22",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - A hepatitis C-vírus-fertozés szurése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása

T2 - Magyar konszenzusajánlás

AU - Hunyady, B.

AU - Zsuzsanna, Gerlei

AU - Judit, Gervain

AU - Gábor, Horváth

AU - Lengyel, G.

AU - Pár, A.

AU - Zoltán, Péter

AU - László, Rókusz

AU - Ferenc, Schneider

AU - Szalay, F.

AU - István, Tornai

AU - Klára, Werling

AU - Mihály, Makara

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred.

AB - Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred.

KW - Direct acting antiviral drug

KW - Genotype

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Interferon

KW - Liver cirrhosis

KW - Polymerase inhibitor

KW - Protease inhibitor

KW - Replication complex inhibitor

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85014136846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014136846&partnerID=8YFLogxK

U2 - 10.1556/650.2017.30688

DO - 10.1556/650.2017.30688

M3 - Article

C2 - 28218867

AN - SCOPUS:85014136846

VL - 158

SP - 3

EP - 22

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -